Effects of Metformin on hepatic venous pressure gradient in patients with cirrhosis and portal hypertension – A randomized placebo-controlled study

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-508535-32-00

Acronym

APHP230872

Enrollment

Registered

2024-09-04

Start date

2025-03-04

Completion date

Unknown

Last updated

2025-07-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Portal hypertension (PHT) and consequences in complications of cirrhosis

Brief summary

the hepatic venous pressure gradient (HVPG) after 28 days of treatment, Endpoints of the ancillary study: Changes in systemic haemodynamics and HVPG 30 minutes after a meal consisting of two 200 mL bottles of hypercaloric/hyperprotic Fortimel Energy

Interventions

DRUGMETFORMIN

DRUGPlacebo 515

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
the hepatic venous pressure gradient (HVPG) after 28 days of treatment, Endpoints of the ancillary study: Changes in systemic haemodynamics and HVPG 30 minutes after a meal consisting of two 200 mL bottles of hypercaloric/hyperprotic Fortimel Energy	—

Countries

France

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026